Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact

Okairos Publications

Home » Okairos Publications
0

A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA

ABSTRACT BACKGROUND The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority for [...]

READ MORE
0

Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections

ABSTRACT Human respiratory syncytial virus (HRSV) is a major cause of lower respiratory tract disease in children and the elderly for which there is still no effective vaccine. We have previously [...]

READ MORE
0

Chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine is safe and expands humoral and cellular immunity in adults

ABSTRACT Respiratory syncytial virus (RSV) causes respiratory infection in annual epidemics, with infants and the elderly at particular risk of developing severe disease and death. However, [...]

READ MORE
0

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

ABSTRACT A protective vaccine against hepatitis C virus (HCV) remains an unmet clinical need. HCV infects millions of people worldwide and is a leading cause of liver cirrhosis and hepatocellular [...]

READ MORE
0

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

ABSTRACT Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) [...]

READ MORE
0

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

ABSTRACT Induction of antigen-specific CD8+ T cells offers the prospect of immunization against many infectious diseases, but no subunit vaccine has induced CD8+ T cells that correlate with [...]

READ MORE
0

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

ABSTRACT Whether you’re talking about drafting for a professional sports team or hiring new lab staff, increasing the number of candidates improves your chances of the truly exceptional [...]

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!